Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)

C. L. Vogel, J. M. Denefrio, L. C. Padgett, M. A. Silverman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


In a phase I trail, 2,3-dihydro-1H-imidazo[1,2-b]pyrazole was administered iv weekly at doses ranging from 0.1 to 3.0 g/m2/wk to patients with refractory metastatic solid tumors. Although gastrointestinal toxicity was tolerable and neither granulocyte nor platelet toxicity was seen, significant dose-limiting hemolysis was encountered at doses of 1.5 g/m2/wk. While no definite tumor regressions were seen in the 32 patients evaluable for response, two patients (squamous cell carcinoma of lung and tonsil) had clinically useful improvement.

Original languageEnglish (US)
Pages (from-to)1153-1156
Number of pages4
JournalCancer Treatment Reports
Issue number10-11
StatePublished - Dec 1 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)'. Together they form a unique fingerprint.

Cite this